The use of glucocorticoids, for example, has caused muscle atrophy (26), osteoporosis, obesity, cataracts, necrosis of the femoral head and immunosuppression (27), while IFN-β and natalizumab were respectively predicted to have 62% and 80% annual recurrence and 2-year disability deterioration in MS patients receiving their first treatment (28, 29). Here, IFNB1 is linked to obesity due to melanocortin 4 receptor deficiency.